William P. Forbes serves as EVP, Chief Development Officer of HERON THERAPEUTICS, INC. (HRTX). Forbes has also held reporting roles at Beyond Air, Inc. (XAIR). Forbes has reported 19 insider filings with the SEC since 2024. The most recent filing was in August 2026.
Every role William P. Forbes has reported on a Form 4, reconstructed from the filings themselves. Reporting insiders must state their relationship to the issuer (officer title, director seat, or 10% ownership) on every filing.
HERON THERAPEUTICS, INC. /DE/ (HRTX)3 filingsUpdated Aug 31, 2026
William P. Forbes is EVP, Chief Development Officer of HERON THERAPEUTICS, INC. /DE/ (HRTX). 14 SEC Form 4 filings on record going back to 2024, most recently on 3 August 2026.
Every recent SEC Form 4 transaction William P. Forbes has reported, most recent first.
InsiderAlpha's records for William P. Forbes go back to 2024: 14 primary Form 4 filings, an average of 4.7 per year. No transaction on record carries a Rule 10b5-1 flag - the filings look discretionary rather than pre-scheduled, which makes their timing more informative as a signal.
Insiders who have reported open-market trades at the same companies as William P. Forbes. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
Other corporate insiders with significant SEC Form 4 track records on InsiderAlpha:
William P. Forbes is a corporate insider, tracked as EVP, Chief Development Officer of HERON THERAPEUTICS, INC. /DE/ (HRTX). InsiderAlpha holds 14 primary Form 4 filings for them, the earliest from 2024, updated as new SEC EDGAR filings are processed.
3 primary Form 4 filings in the last 90 days, covering 1 company.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
A free account opens the full scored daily plan and every past day, a watchlist for any ticker, and 3 months of price history on every company page. No card.
Free plan available · Paid plans start with a 7-day free trial
$HRTX HERON THERAPEUTICS, INC. /DE/3.3K shares @ $0.50$2K